133 related articles for article (PubMed ID: 29429124)
1. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status.
Limon D; Gal O; Gordon N; Katz L; Perl G; Purim O; Amit L; Stemmer SM; Kundel Y; Ben-Aharon I; Brenner B; Siegal T; Yust-Katz S
J Neurooncol; 2018 Jun; 138(2):315-320. PubMed ID: 29429124
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
4. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
5. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
6. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.
Jung J; Lee SH; Park M; Youn JH; Shin SH; Gwak HS; Yoo H
J Neurooncol; 2018 Apr; 137(2):295-302. PubMed ID: 29260362
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
8. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer.
Xu Z; Marko NF; Chao ST; Angelov L; Vogelbaum MA; Suh JH; Barnett GH; Weil RJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e739-47. PubMed ID: 22024205
[TBL] [Abstract][Full Text] [Related]
9. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
Kim YJ; Kim JS; Kim IA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
[TBL] [Abstract][Full Text] [Related]
12. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
[TBL] [Abstract][Full Text] [Related]
13. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
Matsuo S; Watanabe J; Mitsuya K; Hayashi N; Nakasu Y; Hayashi M
Breast Cancer Res Treat; 2017 Feb; 162(1):169-179. PubMed ID: 28084583
[TBL] [Abstract][Full Text] [Related]
14. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.
Tonyali O; Coskun U; Yuksel S; Inanc M; Bal O; Akman T; Yazilitas D; Ulas A; Kucukoner M; Aksoy A; Demirci U; Uysal M; Tanriverdi O; Gunaydin Y; Sumbul AT; Yildiz R; Karaca H; Oksuzoglu B; Ciltas A; Buyukberber S; Benekli M;
Breast; 2016 Feb; 25():22-6. PubMed ID: 26801412
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
18. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
19. The relationship between brain metastasis and HER2 expression status in gastric cancer.
Lai MY; Guan WL; Yang J; Sun YT; Lu SX; Yang LQ; Yang DJ; Qiu MZ
Clin Transl Oncol; 2024 Mar; 26(3):765-773. PubMed ID: 37620706
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.
Killelea BK; Chagpar AB; Horowitz NR; Lannin DR
Am J Surg; 2017 Feb; 213(2):426-432. PubMed ID: 27769548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
